{"id":43015,"date":"2021-10-19T15:44:03","date_gmt":"2021-10-19T14:44:03","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=43015"},"modified":"2021-10-19T15:44:03","modified_gmt":"2021-10-19T14:44:03","slug":"domenica-lorusso-esmo-2021-relacorilant-in-combination-with-nab-paclitaxel-for-patients-with-recurrent-platinum-resistant-ovarian-cancer","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/ovarian-cancer\/conference-hub\/domenica-lorusso-esmo-2021-relacorilant-in-combination-with-nab-paclitaxel-for-patients-with-recurrent-platinum-resistant-ovarian-cancer\/","title":{"rendered":"Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer"},"content":{"rendered":"

touchONCOLOGY joins Dr Domenica Lorusso<\/strong> (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812<\/a>)<\/p>\n

Question
\n<\/strong>Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel.<\/p>\n